Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Conducting $845 Million IPO in Hong Kong

publication date: Sep 17, 2020

Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise $845 million, based on the price of the company's US-listed shares. On the NASDAQ Exchange, Zai has a market capitalization of $6.2 billion. The company is developing a large portfolio of in-licensed cancer and infectious disease candidates. Its PARP inhibitor is approved for China use in ovarian cancer and a medical device, Tumor Treating Fields, is approved in China for glioblastoma. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here